Ribo announces the latest research news for three siRNA therapeutic drugs at the European Society of Cardiology Congress 2023

Suzhou Ribo Life Science (Ribo) and Ribocure Pharmaceuticals (Ribocure) presented new data from three projects from its cardiovascular pipeline at the European Society of Cardiology Congress (ESC) in Amsterdam on August 25-28, the world’s largest and most influential conference in cardiology. Building on its proprietary liver-targeting platform RIBO-GalSTAR®, highly specific, potent and durable gene silencing […]

Promising data from our HBV program presented at EASL Congress

Thanks EASL for a great meeting and also the opportunity to simultaneously show data from our HBV program, both with regard to its robust preclinical proof of concept data package as well as the hot off the press interim clinical data from the ongoing Ph1b study. Very excited to see the excellent safety data and […]

Ribocure Pharmaceuticals was officially inaugurated on June 30th 2023

We arranged our inauguration ceremony together with both friends and colleagues from academia and industry, as well as many persons that have contributed to the establishment of Ribocure Pharmaceuticals during the past year. Over 75 persons participated, and guests of honor was the leadership team from the mother company Suzhou Ribo Life Science. And who […]